DOXORUBICINE TEVA 50 mg/25 ml, solution injectable clinical trials

Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas

This study is looking for adult patients with a certain type of advanced soft tissue sarcoma. It compares a new drug, LB-100, combined with standard doxorubicin treatment, against doxorubicin alone, to see how well it works and if it's safe.